PAVmed Inc. (PAVM) intrinsic value & 10-year financials
PAVmed Inc. (PAVM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 38.6% a year to $71.0K, with an average return on invested capital of 728.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.41
- Market cap
- $1.6M
- Revenue (FY2025)
- $71.0K
- Revenue growth (10-yr CAGR)
- -38.6%
- ROIC (10-yr avg)
- 728.8%
- Free cash flow (FY2025)
- -$5.2M
PAVM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $71.0K | $401.0K | -$5.63 | -$5.2M | -30712.7% | -133.5% |
| FY2024 | $3.0M | $39.8M | $0.50 | -$33.6M | -1485.4% | 123.7% |
| FY2023 | $2.5M | -$64.2M | -$1.02 | -$52.3M | -2805.7% | 108.7% |
| FY2022 | $377.0K | -$89.0M | -$1.67 | -$72.5M | -24118.6% | 187.0% |
| FY2021 | $500.0K | -$50.3M | — | -$42.1M | -10878.6% | -158.4% |
| FY2020 | — | -$34.3M | — | -$22.0M | — | 3555.9% |
| FY2019 | — | -$16.5M | — | -$13.4M | — | 536.2% |
| FY2018 | — | -$18.0M | — | -$8.8M | — | 696.1% |
| FY2017 | — | -$9.5M | — | -$6.6M | — | 601.1% |
| FY2016 | — | -$5.7M | — | -$4.5M | — | 1771.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PAVmed Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PAVmed Inc. has earned high returns on invested capital, averaging 17.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Over the decade, PAVmed Inc. shows that management has aggressively returned capital to shareholders by retiring 99.4% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PAVmed Inc. is modeled at -38.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-29.64 per share.